Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
8
×
national blog main
8
×
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
boston blog main
boston top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
gene therapy
indiana blog main
indiana top stories
deals
glaxosmithkline
nonalcoholic steatohepatitis
amgen
cancer immunotherapy
clinical trials
curevac
europe blog main
europe top stories
gilead sciences
merck
What
bio
8
×
cancer
8
×
roundup
pharmaceutical
promise
vaccine
amid
bombast
caught
companies
coronavirus
debate
develop
discussion
efforts
hasn’t
immunotherapy
meso’s
miss
new
pandemic
pfizer’s
presidential
response
tuesday’s
viewers
abbvie’s
advanced
ahead
allogene
appetite
approved
arrival
award
bets
biofourmis
black
bread
bucks
butter
Language
unset
Current search:
cancer
×
" national blog main "
×
" life sciences "
×
bio
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines